

# Ho Yeong Lim

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2071929/ho-yeong-lim-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

193  
papers

6,919  
citations

32  
h-index

81  
g-index

202  
ext. papers

10,427  
ext. citations

4.9  
avg, IF

5.79  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 193 | Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 1894-1905  | 59.2 | 1496      |
| 192 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased $\alpha$ -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2019</b> , 20, 282-296   | 21.7 | 704       |
| 191 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 193-202 <sup>2,2</sup>  | 22.2 | 600       |
| 190 | Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. <i>Nature Medicine</i> , <b>2018</b> , 24, 1449-1458   | 50.5 | 577       |
| 189 | Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 57-67 <sup>27.4</sup>   | 27.4 | 427       |
| 188 | Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3130-6                 | 2.2  | 271       |
| 187 | Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1630-1637  | 8.7  | 190       |
| 186 | IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 267-267                           | 2.2  | 107       |
| 185 | Aggressive Intrahepatic Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: Risk Factors and Clinical Significance. <i>Radiology</i> , <b>2015</b> , 276, 274-85   | 20.5 | 80        |
| 184 | Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. <i>Cancer Discovery</i> , <b>2019</b> , 9, 1388-1405   | 24.4 | 78        |
| 183 | Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. <i>Oncotarget</i> , <b>2015</b> , 6, 40360-9 <sup>2.3</sup>   | 2.3  | 77        |
| 182 | A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5976-85  | 12.9 | 75        |
| 181 | REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1000-1009 | 2.2  | 62        |
| 180 | Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4508-4508   | 2.2  | 60        |
| 179 | Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. <i>Hepatology</i> , <b>2016</b> , 64, 774-84   | 11.2 | 58        |
| 178 | Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , <b>2017</b> , 8, 77415-77423  | 3.3  | 55        |
| 177 | Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2822-30   | 7.5  | 52        |

|     |  |      |    |
|-----|--|------|----|
| 176 | Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 350-359   | 13.4 | 51 |
| 175 | Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2991-3001  | 2.2  | 51 |
| 174 | Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. <i>Cancer Research and Treatment</i> , <b>2015</b> , 47, 343-61   | 5.2  | 49 |
| 173 | Gastrointestinal malignancies harbor actionable MET exon 14 deletions. <i>Oncotarget</i> , <b>2015</b> , 6, 28211-22   | 3.3  | 48 |
| 172 | NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. <i>Oncotarget</i> , <b>2015</b> , 6, 39028-35   | 3.3  | 46 |
| 171 | c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 165-169  | 3.8  | 44 |
| 170 | Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 1112-21  | 13.4 | 42 |
| 169 | Patient-derived cell models as preclinical tools for genome-directed targeted therapy. <i>Oncotarget</i> , <b>2015</b> , 6, 25619-30   | 3.3  | 42 |
| 168 | An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , <b>2019</b> , 24, 747-e218 | 5.7  | 41 |
| 167 | Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.. <i>Journal of Hepatology</i> , <b>2021</b> ,   | 13.4 | 39 |
| 166 | Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with -Mutated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4650-4661  | 12.9 | 38 |
| 165 | MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. <i>Oncotarget</i> , <b>2016</b> , 7, 43492-43503  | 3.3  | 37 |
| 164 | Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 991-1001  | 21.7 | 37 |
| 163 | Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. <i>Scientific Reports</i> , <b>2019</b> , 9, 15365   | 4.9  | 34 |
| 162 | Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 896-904   | 13.4 | 32 |
| 161 | Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210730   | 3.7  | 32 |
| 160 | Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. <i>Oncotarget</i> , <b>2015</b> , 6, 24320-32   | 3.3  | 31 |
| 159 | The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. <i>BMC Cancer</i> , <b>2016</b> , 16, 120  | 4.8  | 31 |

|     |  |      |    |
|-----|--|------|----|
| 158 | Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 567-572   | 4.3  | 30 |
| 157 | Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 117, 171-7  | 5.3  | 29 |
| 156 | Prognostic Value of Volume-Based Metabolic Parameters Measured by (18)F-FDG PET/CT of Pancreatic Neuroendocrine Tumors. <i>Nuclear Medicine and Molecular Imaging</i> , <b>2014</b> , 48, 180-6  | 1.9  | 27 |
| 155 | A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. <i>Journal of Geriatric Oncology</i> , <b>2017</b> , 8, 170-175                                 | 3.6  | 26 |
| 154 | Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 2527-36  | 6.1  | 26 |
| 153 | Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 476-476 | 2.2  | 26 |
| 152 | The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. <i>Journal of Gastric Cancer</i> , <b>2016</b> , 16, 105-10  | 3.2  | 26 |
| 151 | Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 510-518  | 5.2  | 25 |
| 150 | Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. <i>Investigational New Drugs</i> , <b>2018</b> , 36, 1072-1084                                  | 4.3  | 24 |
| 149 | Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract. <i>Translational Oncology</i> , <b>2018</b> , 11, 37-42   | 4.9  | 22 |
| 148 | Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model. <i>Translational Oncology</i> , <b>2017</b> , 10, 469-475  | 4.9  | 21 |
| 147 | Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>BMC Cancer</i> , <b>2017</b> , 17, 211   | 4.8  | 21 |
| 146 | Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. <i>Scientific Reports</i> , <b>2014</b> , 4, 7592   | 4.9  | 21 |
| 145 | EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 172-172   | 2.2  | 21 |
| 144 | The NEXT-1 (Next generation pERsonalized tX with mULTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , <b>2015</b> , 6, 33358-68  | 3.3  | 21 |
| 143 | Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. <i>ESMO Open</i> , <b>2020</b> , 5,  | 6    | 21 |
| 142 | Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. <i>Journal of Hematology and Oncology</i> , <b>2018</b> , 11, 69  | 22.4 | 20 |
| 141 | Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. <i>Cancer Research and Treatment</i> , <b>2018</b> , 50, 488-494  | 5.2  | 20 |

|     |  |      |    |
|-----|--|------|----|
| 140 | Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. <i>International Journal of Biological Markers</i> , <b>2015</b> , 30, e382-6  | 2.8  | 19 |
| 139 | Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. <i>JCO Precision Oncology</i> , <b>2017</b> , 1,   | 3.6  | 18 |
| 138 | Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. <i>Investigational New Drugs</i> , <b>2017</b> , 35, 782-790 | 4.3  | 17 |
| 137 | Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. <i>Cancer Medicine</i> , <b>2019</b> , 8, 6986-6994  | 4.8  | 17 |
| 136 | Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. <i>Liver International</i> , <b>2020</b> , 40, 2544-2552   | 7.9  | 17 |
| 135 | The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). <i>Journal of Cancer</i> , <b>2017</b> , 8, 1395-1399   | 4.5  | 17 |
| 134 | Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 746-52   | 7.5  | 17 |
| 133 | MerTK is a novel therapeutic target in gastric cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 96656-96667  | 3.3  | 17 |
| 132 | Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data. <i>Cancer Research and Treatment</i> , <b>2016</b> , 48, 1243-1252  | 5.2  | 17 |
| 131 | Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4700-4709  | 12.9 | 17 |
| 130 | Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center experiences. <i>Oncotarget</i> , <b>2017</b> , 8, 42478-42486   | 3.3  | 16 |
| 129 | Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. <i>BMC Cancer</i> , <b>2015</b> , 15, 530                        | 4.8  | 15 |
| 128 | Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 11094-11104   | 3.3  | 15 |
| 127 | MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2508-2508                 | 2.2  | 15 |
| 126 | Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. <i>BMC Cancer</i> , <b>2018</b> , 18, 1103  | 4.8  | 15 |
| 125 | Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2017</b> , 13, 61-67   | 1.9  | 14 |
| 124 | Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , <b>2015</b> , 8, 40-6                               | 4.9  | 14 |
| 123 | Changes in the mean corpuscular volume after capecitabine treatment are associated with clinical response and survival in patients with advanced gastric cancer. <i>Cancer Research and Treatment</i> , <b>2015</b> , 47, 72-7                     | 5.2  | 14 |

|     |   |     |    |
|-----|---|-----|----|
| 122 | A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. <i>BMC Urology</i> , <b>2016</b> , 16, 46   | 2.2 | 13 |
| 121 | Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. <i>Molecular and Clinical Oncology</i> , <b>2017</b> , 7, 27-31  | 1.6 | 13 |
| 120 | Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC). <i>Japanese Journal of Clinical Oncology</i> , <b>2015</b> , 45, 256-60            | 2.8 | 13 |
| 119 | The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. <i>Oncotarget</i> , <b>2017</b> , 8, 3237-3245   | 3.3 | 13 |
| 118 | Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. <i>Journal of Cancer</i> , <b>2016</b> , 7, 1044-8   | 4.5 | 13 |
| 117 | A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. <i>Cancer Research and Treatment</i> , <b>2016</b> , 48, 553-60 | 5.2 | 13 |
| 116 | MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. <i>Oncotarget</i> , <b>2017</b> , 8, 105727-105734   | 12  | 12 |
| 115 | PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. <i>Oncotarget</i> , <b>2015</b> , 6, 40026-35   | 3.5 | 12 |
| 114 | The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation. <i>Journal of Cancer</i> , <b>2017</b> , 8, 2713-2719   | 4.5 | 11 |
| 113 | Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 140-146   | 3.8 | 11 |
| 112 | Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 129, 306-312  | 5.3 | 11 |
| 111 | Clinical features and treatment of collecting duct carcinoma of the kidney from the korean cancer study group genitourinary and gynecology cancer committee. <i>Cancer Research and Treatment</i> , <b>2014</b> , 46, 141-7                   | 5.2 | 11 |
| 110 | Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 1758835921992992                                    | 5.4 | 11 |
| 109 | The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , <b>2017</b> , 8, 2809-2815    | 4.5 | 10 |
| 108 | Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2016</b> , 142, 1231-7                            | 4.9 | 10 |
| 107 | Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. <i>Oncologist</i> , <b>2017</b> , 22, 1169-1177   | 5.7 | 10 |
| 106 | Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. <i>Oncotarget</i> , <b>2016</b> , 7, 19610-9   | 3.3 | 10 |
| 105 | Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 24088-96   | 3.3 | 9  |

|     |   |      |   |
|-----|---|------|---|
| 104 | Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. <i>Radiation Oncology Journal</i> , <b>2016</b> , 34, 34-44   | 2.5  | 9 |
| 103 | Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. <i>Liver Cancer</i> , <b>2021</b> , 10, 275-284   | 9.1  | 9 |
| 102 | Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 1593-1603  | 7.4  | 9 |
| 101 | Comprehensive pharmacogenomic characterization of gastric cancer. <i>Genome Medicine</i> , <b>2020</b> , 12, 17   | 14.4 | 8 |
| 100 | Clinical significance of mucinous rectal adenocarcinoma following preoperative chemoradiotherapy and curative surgery. <i>Tumori</i> , <b>2016</b> , 102, 114-21  | 1.7  | 8 |
| 99  | A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 76-81   | 3.3  | 8 |
| 98  | Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study. <i>Cancer Research and Treatment</i> , <b>2018</b> , 50, 175-182  | 5.2  | 8 |
| 97  | Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. <i>Cancer</i> , <b>2021</b> , 127, 865-874  | 6.4  | 8 |
| 96  | Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. <i>Journal of Gastric Cancer</i> , <b>2018</b> , 18, 348-355   | 3.2  | 8 |
| 95  | Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. <i>Translational Oncology</i> , <b>2015</b> , 8, 288-94   | 4.9  | 7 |
| 94  | Importance of the Circumferential Extent of Tumors and Clinical Lymph Node Status as Prognostic Factors after Preoperative Chemoradiotherapy and Surgery in Patients with Rectal Cancer. <i>Tumori</i> , <b>2010</b> , 96, 568-576  | 1.7  | 7 |
| 93  | Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. <i>Korean Journal of Internal Medicine</i> , <b>2018</b> , 33, 383-390   | 2.5  | 7 |
| 92  | A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 1128-1134  | 5.7  | 7 |
| 91  | Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16). <i>European Journal of Cancer</i> , <b>2020</b> , 127, 183-190  | 7.5  | 7 |
| 90  | The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , <b>2018</b> , 11, 353-357   | 4.9  | 6 |
| 89  | Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. <i>BMC Cancer</i> , <b>2015</b> , 15, 747   | 4.8  | 6 |
| 88  | A multicenter, randomized, phase Ib/II trial of the oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in Asian patients with MET-positive (MET+) advanced hepatocellular carcinoma (HCC) and Child-Pugh Class A liver function.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS4151-TPS4151 | 2.2  | 6 |
| 87  | Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4088-4088                                       | 2.2  | 6 |

|    |  |     |   |
|----|--|-----|---|
| 86 | Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4073-4073    | 2.2 | 6 |
| 85 | Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein $\geq 400$ ng/mL: A Matching-Adjusted Indirect Comparison. <i>Advances in Therapy</i> , <b>2021</b> , 38, 2472-2490                  | 4.1 | 6 |
| 84 | Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. <i>Translational Oncology</i> , <b>2019</b> , 12, 597-601  | 4.9 | 5 |
| 83 | The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. <i>Journal of Cancer</i> , <b>2018</b> , 9, 1791-1796                               | 4.5 | 5 |
| 82 | Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. <i>Journal of Cancer</i> , <b>2018</b> , 9, 2910-2915  | 4.5 | 5 |
| 81 | A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer. <i>BMC Urology</i> , <b>2017</b> , 17, 63   | 2.2 | 5 |
| 80 | Comparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naive RCC (COMPARZ).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 366-366           | 2.2 | 5 |
| 79 | Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. <i>Liver International</i> , <b>2021</b> ,   | 7.9 | 5 |
| 78 | Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.. <i>Liver Cancer</i> , <b>2022</b> , 11, 38-47  | 9.1 | 5 |
| 77 | Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 876-885  | 5.2 | 5 |
| 76 | First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920926796   | 5.4 | 5 |
| 75 | Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 200-208  | 8.7 | 5 |
| 74 | Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 83, 501-508   | 3.5 | 5 |
| 73 | Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 268-268 | 2.2 | 5 |
| 72 | The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , <b>2019</b> , 10, 1611-1615  | 4.5 | 4 |
| 71 | Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer.. <i>Translational Cancer Research</i> , <b>2020</b> , 9, 3367-3374   | 0.3 | 4 |
| 70 | Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients ( $\leq 5$ Years) With Gastric Cancer. <i>Anticancer Research</i> , <b>2019</b> , 39, 5811-5820   | 2.3 | 4 |
| 69 | The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. <i>OncoTargets and Therapy</i> , <b>2019</b> , 12, 225-231  | 4.4 | 4 |



|    |   |      |   |
|----|---|------|---|
| 68 | Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. <i>Journal of Cancer</i> , <b>2018</b> , 9, 3394-3399  | 4.5  | 4 |
| 67 | Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists. <i>Expert Opinion on Emerging Drugs</i> , <b>2017</b> , 22, 191-200  | 3.7  | 3 |
| 66 | Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920965842   | 5.4  | 3 |
| 65 | The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. <i>Journal of Cancer</i> , <b>2019</b> , 10, 3140-3144   | 4.5  | 3 |
| 64 | Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4596-4596 | 2.2  | 3 |
| 63 | Sequential treatment with sorafenib (SOR) followed by regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e16680-e16680      | 2.2  | 3 |
| 62 | Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 526-526                               | 2.2  | 3 |
| 61 | The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. <i>Oncotarget</i> , <b>2017</b> , 8, 73974-73980   | 3.3  | 3 |
| 60 | Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter?. <i>Cancers</i> , <b>2020</b> , 12,   | 6.6  | 3 |
| 59 | Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. <i>Journal of Cancer</i> , <b>2019</b> , 10, 6185-6190  | 4.5  | 3 |
| 58 | Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). <i>Liver Cancer</i> , <b>2021</b> , 10, 451-460  | 9.1  | 3 |
| 57 | TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. <i>Pathology Research and Practice</i> , <b>2020</b> , 216, 152820  | 3.4  | 2 |
| 56 | Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. <i>Journal of Oncology</i> , <b>2020</b> , 2020, 4659062  | 4.5  | 2 |
| 55 | Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial.. <i>Genome Medicine</i> , <b>2022</b> , 14, 1   | 14.4 | 2 |
| 54 | Tolerability and activity of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4072-4072   | 2.2  | 2 |
| 53 | Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4078-4078   | 2.2  | 2 |
| 52 | Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Interim analysis of the prospective, observational REFINE trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 542-542                                   | 2.2  | 2 |
| 51 | Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 550-550  | 2.2  | 2 |

|    |  |     |   |
|----|--|-----|---|
| 50 | Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer. <i>Cancer Research and Treatment</i> , <b>2020</b> , 52, 446-454  | 5.2 | 2 |
| 49 | Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. <i>American Journal of Translational Research (discontinued)</i> , <b>2019</b> , 11, 4508-4515  | 3   | 2 |
| 48 | Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4049-4049   | 2.2 | 2 |
| 47 | Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. <i>Oncology</i> , <b>2021</b> , 99, 365-372  | 3.6 | 2 |
| 46 | Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , <b>2021</b> , 12, 460-466   | 4.5 | 2 |
| 45 | Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study. <i>Cancer</i> , <b>2021</b> , 127, 4585-4593   | 6.4 | 2 |
| 44 | Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. <i>Anticancer Research</i> , <b>2014</b> , 34, 6585-91   | 2.3 | 2 |
| 43 | Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. <i>Targeted Oncology</i> , <b>2020</b> , 15, 185-192   | 5   | 1 |
| 42 | An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients. <i>Journal of Cancer</i> , <b>2017</b> , 8, 730-736  | 4.5 | 1 |
| 41 | Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 433-433                                     | 2.2 | 1 |
| 40 | Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3608-3608 | 2.2 | 1 |
| 39 | Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2522-2522  | 2.2 | 1 |
| 38 | Phase II XELOX + lapatinib treatment in HER2-amplified gastric cancer: Monitoring with serial cell-free DNA genomics.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15610-e15610   | 2.2 | 1 |
| 37 | First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e14501-e14501   | 2.2 | 1 |
| 36 | First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3104-3104  | 2.2 | 1 |
| 35 | Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin unfit patients with advanced urothelial carcinoma: A randomized phase II study (COACH, KCSG GU10-16).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4534-4534   | 2.2 | 1 |
| 34 | Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 549-549  | 2.2 | 1 |
| 33 | Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3023-3023   | 2.2 | 1 |

|    |   |     |   |
|----|---|-----|---|
| 32 | Safety and efficacy of everolimus in Asian patients with metastatic renal cell carcinoma (mRCC) who failed previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapy: A subanalysis of REACT.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e15064-e15064 | 2.2 | 1 |
| 31 | Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 1059-1067   | 5.9 | 1 |
| 30 | Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4072-4072                                | 2.2 | 1 |
| 29 | Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer.. <i>Annals of Surgical Oncology</i> , <b>2022</b> , 1  | 3.1 | 1 |
| 28 | Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 436-436  | 2.2 | 0 |
| 27 | Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Multicenter phase 2 trial (RENOBATE).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 415-415   | 2.2 | 0 |
| 26 | Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. <i>Clinical Drug Investigation</i> , <b>2021</b> , 41, 795-808  | 3.2 | 0 |
| 25 | ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy. <i>In Vivo</i> , <b>2021</b> , 35, 499-505  | 2.3 | 0 |
| 24 | A clinical scoring system for survival prediction in advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 436-436  | 2.2 |   |
| 23 | Identification of Leukemia Surface Proteins Using a Proteomic Technique. <i>The Korean Journal of Hematology</i> , <b>2006</b> , 41, 272  |     |   |
| 22 | VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e24234-e24234  | 2.2 |   |
| 21 | Detection of targetable fusions using FusionPlex in oncology patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e24238-e24238   | 2.2 |   |
| 20 | The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 213-213   | 2.2 |   |
| 19 | Gemcitabine-carboplatin (GCb) versus gemcitabine-oxaliplatin (GemOx) in cisplatin un-fit advanced urothelial carcinoma: Randomized phase II study (COACH Study).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 355-355   | 2.2 |   |
| 18 | Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs.. <i>Translational Cancer Research</i> , <b>2019</b> , 8, 2107-2112   | 0.3 |   |
| 17 | Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4008-4008   | 2.2 |   |
| 16 | Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3576-3576  | 2.2 |   |
| 15 | Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e22241-e22241  | 2.2 |   |

|    |   |     |
|----|---|-----|
| 14 | Tuberous sclerosis complex 2 (TSC2) expression in hepatocellular carcinoma to predict responses to mTOR inhibitor.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e15628-e15628   | 2.2 |
| 13 | The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institution.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4091-4091   | 2.2 |
| 12 | The impact of cetuximab plus AKT- or mTOR- inhibitor in patient-derived colon cancer cell model with RAS wild type and PIK3CA mutation.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e15153-e15153  | 2.2 |
| 11 | Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e14622-e14622   | 2.2 |
| 10 | The impact of pathologic differentiation (well/ poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15686-e15686  | 2.2 |
| 9  | Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14617-e14617 | 2.2 |
| 8  | A phase Ib dose escalation study of JX-594 (TK-vaccinia virus expressing GM-CSF) administered by biweekly intravenous infusion in patients with metastatic, refractory colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e13044-e13044                               | 2.2 |
| 7  | Efficacy and toxicity of sunitinib in renal insufficiency patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e15573-e15573   | 2.2 |
| 6  | A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e15613-e15613  | 2.2 |
| 5  | Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e16122-e16122  | 2.2 |
| 4  | Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients. <i>Targeted Oncology</i> , <b>2020</b> , 15, 203-209  | 5   |
| 3  | When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer. <i>Journal of Cancer</i> , <b>2021</b> , 12, 5681-5686   | 4.5 |
| 2  | Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 318-318      | 2.2 |
| 1  | The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 1  | 4.9 |